☆ 4.7 Article

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

ANNALS OF ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Surgery

Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study

Gabriele Martelli et al.

Summary: The study confirms that in cN0/1 breast cancer patients who undergo primary chemotherapy followed by sentinel node biopsy, if the sentinel nodes are clear (pN0), performing only SNB can be an effective axillary treatment without impacting overall survival or disease-free survival.

ANNALS OF SURGERY (2022)

Add to Collection

Article Surgery

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients

Sherko Kuemmel et al.

Summary: The study demonstrates the feasibility of TAD in a real-world cohort of breast cancer patients, which is of great importance for the de-escalation of surgical strategies.

ANNALS OF SURGERY (2022)

Add to Collection

Article Oncology

Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

Muayad F. Almahariq et al.

Summary: The study compared the survival outcomes of breast cancer patients with residual lymph node disease who underwent sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) using the National Cancer Database (NCDB). The results showed that SLND was associated with lower survival rates compared to ALND in matched cohorts, suggesting that ALND may be preferred over SLND for patients with residual lymph node disease. Further prospective trials are needed to confirm the efficacy of SLND in this patient population.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer

Stephanie M. Wong et al.

Summary: This study demonstrates that sentinel lymph node biopsy alone for patients who convert to pathologic node-negativity after neoadjuvant chemotherapy is associated with low short-term axillary recurrence rates. Additional follow-up data from prospective clinical trials are needed to confirm long-term oncologic safety and optimal local therapy recommendations.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Arlene Chan et al.

Summary: In early-stage breast cancer patients, neratinib provides a 5.1% increase in invasive disease-free survival and a 2.1% increase in overall survival at 8 years compared to placebo. For patients with residual disease after neoadjuvant therapy, the absolute benefits of neratinib are 7.4% and 9.1%, respectively.

CLINICAL BREAST CANCER (2021)

Add to Collection

Article Oncology

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

Erika Hamilton et al.

Summary: Abemaciclib showed single-agent activity in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. Adding tamoxifen did not significantly improve progression-free survival or objective response rate compared to abemaciclib monotherapy.

CLINICAL BREAST CANCER (2021)

Add to Collection

Article Oncology

Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up

Sabrina Kahler-Ribeiro-Fontana et al.

Summary: This study evaluated the outcomes of patients undergoing NAT who remained or converted to cN0 and received SNB, showing a high overall survival rate after 10-year follow-up. The use of standard SNB in cN1/2 patients who become cN0 after NAT was deemed acceptable and did not result in worse outcomes.

EJSO (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The Impact of the COVID-19 Pandemic on Breast Imaging

Phoebe E. Freer

RADIOLOGIC CLINICS OF NORTH AMERICA (2021)

Add to Collection

Article Oncology

The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report

G. N. Marta et al.

Summary: This study evaluated the financial impact of moderately hypofractionated breast irradiation in different countries, finding that financial loss for healthcare providers induced by fee-for-service remuneration may hinder the widespread adoption of these regimens. It is suggested that an alternative system of remuneration, such as bundled payments based on stage and diagnosis, may provide more value for all stakeholders.

CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial

Xi Wang et al.

Summary: This study aimed to evaluate the efficacy and adverse effects of low-dose capecitabine maintenance therapy after standard adjuvant chemotherapy in early-stage triple-negative breast cancer. The results showed significantly improved 5-year disease-free survival in patients receiving capecitabine treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Torsten O. Nielsen et al.

Summary: Ki67 immunohistochemistry (IHC) is commonly used in breast cancer as a proliferation marker, but its analytical validity has been questioned. The International Ki67 in Breast Cancer Working Group (IKWG) recommends careful preanalytical handling, adoption of a standardized visual scoring method, and participation in quality assurance and quality control programs. Clinical utility of Ki67 IHC in breast cancer care is currently limited to prognosis assessment in stage I or II breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Review Oncology

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox

Peter Dubsky et al.

Summary: An international consortium was established to provide clinical guidance and tools for the technical management of patients with early-stage breast cancer through discussions and consensus meetings. During the meeting, 42% of statements reached a consensus, 38% were supported by the majority, and 21% did not reach a decision.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer et al.

Summary: The PALLAS trial investigated whether adding 2 years of palbociclib to adjuvant endocrine therapy could improve invasive disease-free survival in early-stage hormone-receptor-positive, HER2-negative breast cancer patients, but the results showed no significant benefit. The trial was then discontinued based on the lack of efficacy observed during the planned second interim analysis.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

A Population-Based Study of Genes Previously Implicated in Breast Cancer

Chunling Hu et al.

Summary: This study provides population-based estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known cancer-predisposition genes. The results highlight the varying levels of risk associated with different genes, such as high risk for BRCA1 and BRCA2 and moderate risk for PALB2, as well as associations with specific subtypes of breast cancer for genes like RAD51C and RAD51D.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

Leila Dorling et al.

Summary: This study sequenced samples from 60,466 women with breast cancer and 53,461 controls using a panel of 34 putative susceptibility genes, identifying associations between protein-truncating variants in certain genes and breast cancer risk. The results provide important information for genetic counseling and define genes that are most clinically useful for predicting breast cancer risk.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study

Atilla Soran et al.

Summary: The study demonstrated that locoregional treatment can prolong survival and reduce local recurrence in patients with de novo stage IV bone-only metastatic breast cancer. The timing of primary breast surgery provides a survival benefit similar to systemic treatment alone in these patients.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto

Fatima Cardoso et al.

Summary: In Europe, inappropriate reimbursement policies hinder optimal breast cancer care and were discussed in the 12th European Breast Cancer Conference. Patient involvement is crucial in driving changes to clinical practice. While reimbursement policies may differ among European countries, similar issues exist and broad solutions can be applied to improve care.

BREAST (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures

Sarah J. Nyante et al.

Summary: Pandemic-related decreases in breast examinations gradually improved over time, with fewer exams than expected initially. Women receiving breast care during the pandemic had higher predicted breast cancer risk and were more likely to lack insurance compared to before the pandemic. Further long-term studies are needed to understand the impact of these trends on breast cancer disparities.

CANCER (2021)

Add to Collection

Article Oncology

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Tomas Pascual et al.

Summary: In HR+/HER2+ breast cancer, the PAM50-based CES score can predict sensitivity to chemo-endocrine therapy and provide additional prognostic information beyond intrinsic subtype and clinicopathologic characteristics. High CES is associated with lower pCR probability and better DFS.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart et al.

Summary: The PURPOSEAPHINITY study demonstrates that adding pertuzumab to adjuvant therapy with trastuzumab and chemotherapy significantly improves invasive disease-free survival for early HER2-positive breast cancer patients. Longer follow-up is needed for a comprehensive assessment of overall survival benefits.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer et al.

Summary: Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy, indicating potential for further research in specific patient subpopulations and combination therapy for this disease.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart et al.

Summary: The MINDACT trial demonstrated that patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy had excellent 5-year distant metastasis-free survival. The long-term follow-up results, including exploratory analysis by age, further support the use of genomic testing in identifying patients who can forgo chemotherapy. Chemotherapy showed different effects on distant metastasis-free survival based on age and nodal status, especially in hormone receptor-positive, HER2-negative disease.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials

Sonia L. Villegas et al.

Summary: The study found that patients with low hormone receptor expression HER2-negative breast cancer had similar treatment response and survival rates as patients with triple-negative breast cancer, while patients with strong hormone receptor-positive breast cancer had a lower pathological complete response rate but better survival rates. Low hormone receptor expression breast cancer patients were predominantly classified into a basal-like subtype based on gene expression analysis.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

Sibylle Loibl et al.

Summary: The study investigated the efficacy of palbociclib in breast cancer patients with residual invasive disease after neoadjuvant chemotherapy, showing that palbociclib in addition to endocrine therapy did not improve invasive disease-free survival. Some related serious adverse events were reported, but no significant difference between treatment arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Disruptions in preventive care: Mammograms during the COVID-19 pandemic

Hummy Song et al.

Summary: The provision of mammograms has been significantly disrupted due to the COVID-19 pandemic, with a sharp decline in the volume of screening and diagnostic mammograms, although they gradually rebounded in the following weeks.

HEALTH SERVICES RESEARCH (2021)

Add to Collection

Article Oncology

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Olivia Pagani et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Francesco Schettini et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Article Oncology

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial

Gerd Fastner et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Ana Lluch et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Karin Ribi et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

Add to Collection

Editorial Material Oncology

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Jill R. Dietz et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

Add to Collection

Editorial Material Oncology

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic

C. E. Coles et al.

CLINICAL ONCOLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer

Allison W. Kurian et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt et al.

LANCET (2020)

Add to Collection

Article Oncology

A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting

Pedro Sanchez-Rovira et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer

Ivana Sestak et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer

Mara A. Piltin et al.

ANNALS OF SURGICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial

Peter C. Dubsky et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Adrian Murray Brunt et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

Evandro de Azambuja et al.

ESMO OPEN (2020)

Add to Collection

Meeting Abstract Oncology

Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D. W. Miles et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)

A. Bardia et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Knowledge gaps in oncoplastic breast surgery

Walter P Weber et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial

Birgitte V. Offersen et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial

Icro Meattini et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Stephen R. D. Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

Add to Collection

Article Oncology

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Nadine M. Tung et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortes et al.

LANCET (2020)

Add to Collection

Article Oncology

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

Philip M. Poortmans et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Harold J. Burstein

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Apples and oranges: comparing partial breast irradiation techniques

Orit Kaidar-Person et al.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2020)

Add to Collection

Article Oncology

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

Hee Jeong Kim et al.

BREAST CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603)

Roberto A. Leon-Ferre et al.

JNCI CANCER SPECTRUM (2020)

Add to Collection

Article Oncology

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

Shu-Lian Wang et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII+IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

Carsten Denkert et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Joseph A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

S. -A. Im et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer

Orit Kaidar-Person et al.

RADIOTHERAPY AND ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Oncology

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

H. J. Burstein et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

J. M. S. Bartlett et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Patient-Reported Outcomes Over 5 Years After Whole-or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial

Indrani S. Bhattacharya et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial

Timothy J. Whelan et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

Frank A. Vicini et al.

LANCET (2019)

Add to Collection

Article Oncology

Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Tracy-Ann Moo et al.

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01

Atilla Soran et al.

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Irene L. Wapnir et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, Research & Experimental

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial

Guido Henke et al.

TRIALS (2018)

Add to Collection

Article Medicine, General & Internal

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Hope S. Rugo et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Article Medicine, General & Internal

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial

Armando E. Giuliano et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Review Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Hongchao Pan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Surgery

Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer

Reshma Jagsi et al.

JAMA SURGERY (2017)

Add to Collection

Article Oncology

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer A Randomized Clinical Trial

Michelle E. Melisko et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer

Nehmat Houssami et al.

BREAST CANCER RESEARCH AND TREATMENT (2017)

Add to Collection

Article Oncology

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes

Saundra S. Buys et al.

CANCER (2017)

Add to Collection

Article Surgery

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)

Judy C. Boughey et al.

ANNALS OF SURGERY (2016)

Add to Collection

Article Oncology

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M. Regan et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Juerg Bernhard et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Mila Donker et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

Stefan Aebi et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

Judy C. Boughey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Oncology

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Kevin S. Hughes et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates

Oreste Gentilini et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

Takayuki Iwamoto et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Editorial Material Medicine, General & Internal

Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer

Tatiana M. Prowell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Editorial Material Oncology

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

Mitch Dowsett et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)

Add to Collection

Article Medicine, General & Internal

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Sandra M. Swain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Oncology

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98

Giuseppe Viale et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

Article Oncology

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Vladimir F. Semiglazov et al.

CANCER (2007)

Add to Collection

Article Medicine, General & Internal

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer

B Fisher et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.